TRAIL-modified, doxorubicin-embedded periodic mesoporous organosilica nanoparticles for targeted drug delivery and efficient antitumor immunotherapy

Morris, 2010, Medical oncology optimizing chemotherapy and radiotherapy for anaplastic glioma, Nat. Rev. Clin. Oncol., 7, 428, 10.1038/nrclinonc.2010.98 Gabizon, 2014, Cancer nanomedicines: closing the translational gap, Lancet, 384, 2175, 10.1016/S0140-6736(14)61457-4 Wang, 2016, Stimuli-responsive programmed specific targeting in nanomedicine, ACS Nano, 10, 2991, 10.1021/acsnano.6b00870 Wang, 2020, Enhancing selective photosensitizer accumulation and oxygen supply for high-efficacy photodynamic therapy toward glioma by 5-aminolevulinic acid loaded nanoplatform, J. Colloid Interface Sci., 565, 483, 10.1016/j.jcis.2020.01.020 Mai, 2020, Biodegradable periodic mesoporous organosilica (BPMO) loaded with daunorubicin: a promising nanoparticle-based anticancer drug, ChemMedChem, 15, 593, 10.1002/cmdc.201900595 Teng, 2014, Yolk-Shell structured mesoporous nanoparticles with thioether-bridged organosilica frameworks, Chem. Mater., 26, 5980, 10.1021/cm502777e Croissant, 2018, Mesoporous silica and organosilica nanoparticles: physical chemistry, biosafety, delivery strategies, and biomedical applications, Adv. Healthc. Mater., 7, 75, 10.1002/adhm.201700831 Du, 2016, Mesoporous silica nanoparticles with organo-bridged silsesquioxane framework as innovative platforms for bioimaging and therapeutic agent delivery, Biomaterials, 91, 90, 10.1016/j.biomaterials.2016.03.019 Teng, 2016, Facile synthesis of yolk-shell-structured triple-hybridized periodic mesoporous organosilica nanoparticles for biomedicine, Small, 12, 3550, 10.1002/smll.201600616 Lu, 2016, Smart cancer cell targeting imaging and drug delivery system by systematically engineering periodic mesoporous organosilica nanoparticles, ACS Appl. Mater. Interfaces, 8, 2985, 10.1021/acsami.5b09585 Liao, 2018, Fabrication of ultrasmall WS2 quantum dots-coated periodic mesoporous organosilica nanoparticles for intracellular drug delivery and synergistic chemo-photothermal therapy, OncoTargets Ther, 11, 12, 10.2147/OTT.S160748 Danhier, 2010, To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery, J. Control. Release, 148, 135, 10.1016/j.jconrel.2010.08.027 Hirsjarvi, 2011, Passive and active tumour targeting with nanocarriers, Curr. Drug Discov. Technol., 8, 188, 10.2174/157016311796798991 Bertrand, 2014, Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology, Adv. Drug Deliv. Rev., 66, 2, 10.1016/j.addr.2013.11.009 Zhang, 2019, Construction of pH responsive periodic mesoporous organosilica with histidine framework (His-PMO) for drug delivery, J. Solid State Chem., 277, 761, 10.1016/j.jssc.2019.07.049 Wu, 2018, Functionalized MoS2 nanosheet-capped periodic mesoporous organosilicas as a multifunctional platform for synergistic targeted chemo-photothermal therapy, Chem. Eng. J., 342, 90, 10.1016/j.cej.2018.02.052 Ho, 2015, A promising "TRAIL" of tanshinones for cancer therapy, Biomedicine, 5, 29, 10.7603/s40681-015-0023-8 Holoch, 2009, TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies, Eur. J. Pharmacol., 625, 63, 10.1016/j.ejphar.2009.06.066 Zhong, 2019, TRAIL-based gene delivery and therapeutic strategies, Acta Pharmacol. Sin., 40, 1373, 10.1038/s41401-019-0287-8 Abdulghani, 2010, TRAIL receptor signaling and therapeutics, Expert Opin. Ther. Targets, 14, 1091, 10.1517/14728222.2010.519701 Yuan, 2018, Developing TRAIL/TRAIL death receptor-based cancer therapies, Cancer Metastasis Rev., 37, 733, 10.1007/s10555-018-9728-y de Looff, 2019, Multiple interactions between cancer cells and the tumor microenvironment modulate TRAIL signaling: implications for TRAIL receptor targeted therapy, Front. Immunol., 10, 15, 10.3389/fimmu.2019.01530 de Miguel, 2016, Onto better TRAILs for cancer treatment, Cell Death Differ., 23, 733, 10.1038/cdd.2015.174 Merino, 2007, TRAIL in cancer therapy: present and future challenges, Expert Opin. Ther. Targets, 11, 1299, 10.1517/14728222.11.10.1299 Thapa, 2020, TRAIL therapy and prospective developments for cancer treatment, J. Control Release, 326, 335, 10.1016/j.jconrel.2020.07.013 Byeon, 2014, Four-arm PEG cross linked hyaluronic acid hydrogels containing PEGylated apoptotic TRAIL protein for treating pancreatic cancer, Acta Biomaterialia, 10, 142, 10.1016/j.actbio.2013.08.046 Lemke, 2014, Getting TRAIL back on track for cancer therapy, Cell Death Differ., 21, 1350, 10.1038/cdd.2014.81 Zhao, 2013, A controlled-release nanocarrier with extracellular pH value driven tumor targeting and translocation for drug delivery, Angew. Chem. Int. Ed., 52, 7487, 10.1002/anie.201302557 Dubowchik, 2002, Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: Model studies of enzymatic drug release and antigen-specific in vitro anticancer activity, Bioconjug. Chem., 13, 855, 10.1021/bc025536j Yan, 2016, Engineered adenovirus fiber shaft fusion homotrimer of soluble TRAIL with enhanced stability and antitumor activity, Cell Death Dis., 7, 11, 10.1038/cddis.2016.177 Wang, 2019, Intercellular adhesion molecule 1 antibody-mediated mesoporous drug delivery system for targeted treatment of triple-negative breast cancer, J. Colloid Interface Sci., 538, 630, 10.1016/j.jcis.2018.12.032 Rao, 2018, Tunable intracellular degradable periodic mesoporous organosilica hybrid nanoparticles for doxorubicin drug delivery in cancer cells, ACS Biomater. Sci. Eng., 4, 175, 10.1021/acsbiomaterials.7b00558 Wang, 2020, Enhancing the antitumor activity of an engineered TRAIL-coated oncolytic adenovirus for treating acute myeloid leukemia, Signal Transduct. Target. Ther., 5, 13 Liu, 2021, Natural melanin-based nanoparticles with combined chemo/photothermal/photodynamic effect induce immunogenic cell death (ICD) on tumor, Front. Bioeng. Biotechnol., 9, 635858, 10.3389/fbioe.2021.635858 Choi, 2020, Doxorubicin-loaded PLGA nanoparticles for cancer therapy: molecular weight effect of PLGA in doxorubicin release for controlling immunogenic cell death, Pharmaceutics, 12, 18, 10.3390/pharmaceutics12121165 Vallhov, 2007, Mesoporous silica particles induce size dependent effects on human dendritic cells, Nano Lett., 7, 3576, 10.1021/nl0714785 Zhou, 2019, Tumor microenvironment-activatable prodrug vesicles for nanoenabled cancer chemoimmunotherapy combining immunogenic cell death induction and CD47 blockade, Adv. Mater., 31, 11, 10.1002/adma.201805888 Zhou, 2019, Immunogenic cell death in cancer therapy: present and emerging inducers, J. Cell. Mol. Med., 23, 4854, 10.1111/jcmm.14356 Hartwig, 2017, The TRAIL-induced cancer secretome promotes a tumor-supportive immune microenvironment via CCR2, Mol. Cell, 65, 730, 10.1016/j.molcel.2017.01.021